Assessment of Renal Dysfunction Improves the Simplified Pulmonary Embolism Severity Index (sPESI) for Risk Stratification in Patients with Acute Pulmonary Embolism.

cardio-renal syndrome chronic kidney disease contrast-induced nephropathy venous thromboembolism

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
01 Feb 2019
Historique:
received: 07 01 2019
revised: 22 01 2019
accepted: 24 01 2019
entrez: 6 2 2019
pubmed: 6 2 2019
medline: 6 2 2019
Statut: epublish

Résumé

Whereas the major strength of the simplified pulmonary embolism severity index (sPESI) lies in ruling out an adverse outcome in patients with sPESI of 0, the accuracy of sPESI ≥ 1 in risk assessment remains questionable. In acute pulmonary embolism (APE), the estimated glomerular filtration rate (eGFR) can be viewed as an integrate marker reflecting not only previous chronic kidney disease (CKD) damage but also comorbid conditions and hemodynamic disturbances associated with APE. We sought to determine whether renal dysfunction assessment by eGFR improves the sPESI score risk stratification in patients with APE. 678 consecutive patients with APE were prospectively enrolled. Renal dysfunction (RD) at diagnosis of APE was defined by eGFR < 60 mL/min/1.73 m² and acute kidney injury (AKI) by elevation of creatinine level >25% during in-hospital stay. RD was observed in 26.9% of the cohort. AKI occurred in 18.8%. A stepwise increase in 30-day mortality, cardiovascular mortality and overall mortality was evident with declining renal function. Multivariate analysis identified RD and CRP (C-reactive protein) level but not sPESI score as independent predictors of 30-day mortality. AKI, 30-day mortality, overall mortality, and cardiovascular mortality were at their highest level in patients with eGFR < 60 mL/min/1.73 m² and sPESI ≥1. in patients with APE, the addition of RD to the sPESI score identifies a specific subset of patients at very high mortality.

Sections du résumé

BACKGROUND BACKGROUND
Whereas the major strength of the simplified pulmonary embolism severity index (sPESI) lies in ruling out an adverse outcome in patients with sPESI of 0, the accuracy of sPESI ≥ 1 in risk assessment remains questionable. In acute pulmonary embolism (APE), the estimated glomerular filtration rate (eGFR) can be viewed as an integrate marker reflecting not only previous chronic kidney disease (CKD) damage but also comorbid conditions and hemodynamic disturbances associated with APE. We sought to determine whether renal dysfunction assessment by eGFR improves the sPESI score risk stratification in patients with APE.
METHODS METHODS
678 consecutive patients with APE were prospectively enrolled. Renal dysfunction (RD) at diagnosis of APE was defined by eGFR < 60 mL/min/1.73 m² and acute kidney injury (AKI) by elevation of creatinine level >25% during in-hospital stay.
RESULTS RESULTS
RD was observed in 26.9% of the cohort. AKI occurred in 18.8%. A stepwise increase in 30-day mortality, cardiovascular mortality and overall mortality was evident with declining renal function. Multivariate analysis identified RD and CRP (C-reactive protein) level but not sPESI score as independent predictors of 30-day mortality. AKI, 30-day mortality, overall mortality, and cardiovascular mortality were at their highest level in patients with eGFR < 60 mL/min/1.73 m² and sPESI ≥1.
CONCLUSION CONCLUSIONS
in patients with APE, the addition of RD to the sPESI score identifies a specific subset of patients at very high mortality.

Identifiants

pubmed: 30717116
pii: jcm8020160
doi: 10.3390/jcm8020160
pmc: PMC6406501
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Lancet. 1999 Apr 24;353(9162):1386-9
pubmed: 10227218
Am J Respir Crit Care Med. 2005 Oct 15;172(8):1041-6
pubmed: 16020800
Eur Heart J. 2006 Feb;27(4):476-81
pubmed: 16207738
Thromb Haemost. 2008 Nov;100(5):937-42
pubmed: 18989541
J Thromb Haemost. 2010 Feb;8(2):409-11
pubmed: 19943871
J Thromb Haemost. 2010 Apr;8(4):651-8
pubmed: 20088923
Nephrol Dial Transplant. 2010 Oct;25(10):3296-301
pubmed: 20353958
J Am Coll Cardiol. 2010 May 11;55(19):2150-7
pubmed: 20447541
Arch Intern Med. 2010 Aug 9;170(15):1383-9
pubmed: 20696966
J Am Coll Cardiol. 2011 Feb 8;57(6):700-6
pubmed: 21292129
Chest. 2012 Apr;141(4):916-922
pubmed: 21852296
Circulation. 2011 Dec 13;124(24):2716-24
pubmed: 22082681
Acad Emerg Med. 2012 Jun;19(6):618-25
pubmed: 22687176
Thromb Res. 2012 Sep;130(3):e37-42
pubmed: 22705059
Heart. 2012 Aug;98(16):1221-8
pubmed: 22705926
Clin J Am Soc Nephrol. 2012 Oct;7(10):1584-90
pubmed: 22837271
Eur Heart J. 2012 Dec;33(24):3014-22
pubmed: 22961946
Thromb Res. 2013;132(6):671-5
pubmed: 24144445
J Thromb Haemost. 2014 Oct;12(10):1658-66
pubmed: 25142085
Circ J. 2015;79(4):889-91
pubmed: 25739720
Circ J. 2016;80(4):980-8
pubmed: 26911363
J Am Coll Cardiol. 2016 Mar 1;67(8):976-90
pubmed: 26916489
Clin Appl Thromb Hemost. 2017 Sep;23(6):554-561
pubmed: 27013086

Auteurs

Antonin Trimaille (A)

Pôle d'Activité Médico-Chirurgicale Cardio-Vasculaire, Nouvel Hôpital Civil, Centre Hospitalier Universitaire, Université de Strasbourg, 67091 Strasbourg, France. antonin.trimaille@chru-strasbourg.fr.

Benjamin Marchandot (B)

Pôle d'Activité Médico-Chirurgicale Cardio-Vasculaire, Nouvel Hôpital Civil, Centre Hospitalier Universitaire, Université de Strasbourg, 67091 Strasbourg, France. benjamin.marchandot@chru-strasbourg.fr.

Mélanie Girardey (M)

Pôle d'Activité Médico-Chirurgicale Cardio-Vasculaire, Nouvel Hôpital Civil, Centre Hospitalier Universitaire, Université de Strasbourg, 67091 Strasbourg, France. melanie.girardey@chru-strasbourg.fr.

Clotilde Muller (C)

Pôle NUDE, Nouvel Hôpital Civil, Centre Hospitalier Universitaire, Université de Strasbourg, 67091 Strasbourg, France. clotilde.muller@chru-strasbourg.fr.

Han S Lim (HS)

Department of Cardiology, Austin and Northern Health, Melbourne 3084, Australia. hanslim@gmail.com.

Annie Trinh (A)

Pôle d'Activité Médico-Chirurgicale Cardio-Vasculaire, Nouvel Hôpital Civil, Centre Hospitalier Universitaire, Université de Strasbourg, 67091 Strasbourg, France. annie.trinh@chru-strasbourg.fr.

Patrick Ohlmann (P)

Pôle d'Activité Médico-Chirurgicale Cardio-Vasculaire, Nouvel Hôpital Civil, Centre Hospitalier Universitaire, Université de Strasbourg, 67091 Strasbourg, France. patrick.ohlmann@chru-strasbourg.fr.

Bruno Moulin (B)

Pôle NUDE, Nouvel Hôpital Civil, Centre Hospitalier Universitaire, Université de Strasbourg, 67091 Strasbourg, France. bruno.moulin@chru-strasbourg.fr.

Laurence Jesel (L)

Pôle d'Activité Médico-Chirurgicale Cardio-Vasculaire, Nouvel Hôpital Civil, Centre Hospitalier Universitaire, Université de Strasbourg, 67091 Strasbourg, France. laurence.jesel@chru-strasbourg.fr.
Laboratory of Regenerative Nanomedicine, UMR 1260, INSERM (French National Institute of Health and Medical Research), FMTS (Fédération de Médecine Translationnelle de l'Université de Strasbourg), Faculté de Médecine, Université de Strasbourg, 11 rue Humann, 67085 Strasbourg, France. laurence.jesel@chru-strasbourg.fr.

Olivier Morel (O)

Pôle d'Activité Médico-Chirurgicale Cardio-Vasculaire, Nouvel Hôpital Civil, Centre Hospitalier Universitaire, Université de Strasbourg, 67091 Strasbourg, France. olivier.morel@chru-strasbourg.fr.
Laboratory of Regenerative Nanomedicine, UMR 1260, INSERM (French National Institute of Health and Medical Research), FMTS (Fédération de Médecine Translationnelle de l'Université de Strasbourg), Faculté de Médecine, Université de Strasbourg, 11 rue Humann, 67085 Strasbourg, France. olivier.morel@chru-strasbourg.fr.

Classifications MeSH